文献速递食管胃疾病与幽门螺杆菌炎症性肠病胃肠动力与功能性疾病

粪菌移植:在胃肠与肝病治疗中的现状

Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-07-25

粪菌移植最初用于抗生素治疗复发性艰难梭菌感染多次失败后修复肠道菌群。由于肠道菌群失调可能参与多种疾病尤其是胃肠疾病的发病,粪菌移植正被探索为优化菌群组成与功能的潜在治疗。本文综述粪菌移植在消化科医生最关注的疾病中的开发与应用现状。

要点

  • 粪菌移植最初用于复发性艰难梭菌感染抗生素治疗多次失败后修复肠道菌群。
  • 肠道菌群失调可能参与多种疾病尤其是胃肠疾病的发病。
  • 粪菌移植正被探索为优化菌群组成与功能的潜在治疗。

核心结论

  • 粪菌移植正被探索为通过优化菌群组成与功能治疗多种胃肠与肝病的潜在方法。

研究设计与样本

  • 本文为综述,总结粪菌移植在消化科医生最关注的疾病中的开发与应用现状。

主要发现

  • 粪菌移植最初在复发性艰难梭菌感染抗生素治疗多次失败后用于修复肠道菌群。
  • 肠道菌群失调可能参与多种疾病尤其是胃肠疾病的发病,因此粪菌移植的应用正被不断探索。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fecal microbiota transplantation was originally introduced as a method to repair intestinal microbiota following failure of multiple treatments of recurrent Clostridiumdifficile infection with antibiotics. However, it is hypothesized that intestinal dysbiosis may contribute to the pathogenesis of many diseases, especially those involving the gastrointestinal tract. Therefore, fecal microbiota transplantation is increasingly being explored as a potential treatment that aims to optimize microbiota composition and functionality. Here, we review the current state of fecal microbiota transplantation development and applications in conditions of greatest interest to a gastroenterologist.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vaughn BP, Rank KM, Khoruts A, et al. Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease. Clin Gastroenterol Hepatol. 2018. PMID: 30055267. doi:10.1016/j.cgh.2018.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。